Expert opinion on biological therapyHumansHemoglobinuriaParoxysmalComplement Inactivating AgentsAntibodies
Progress in the use of biological therapies to treat paroxysmal nocturnal hemoglobinuria: focus on patient profiling.
Francesco Versino, Bruno Fattizzo
Published: 202510.1080/14712598.2025.2574983
Abstract
INTRODUCTION: Complement inhibition has revolutionized paroxysmal nocturnal hemoglobinuria (PNH) treatment. While eculizumab, the first anti-C5 antibody, reduced intravascular hemolysis (IVH) and thrombotic risk, it required fortnightly infusions and…
Preview only. Read the full abstract at the source